# Plasma Fractionation Market

> Plasma Fractionation Market Research Report: Size, Share, Trend Analysis By Applications (Neurology, Hematology, General Medicine, Immunology), By Product Type (Immunoglobulin, Albumin, Coagulation Factors, Protease Inhibitors), By End Users (Hospitals, Ambulatory Surgical Centers, Blood Banks, Pharmaceutical Companies), By Technology (Centrifugation, Chromatography, Precipitation, Filtration) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.59%
- **2024:** $ 31.82 Billion
- **2025:** $ 33.92 Billion
- **2035:** $ 64.22 Billion
- **Key Players:** Companies such as Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company Limited (JP), Octapharma (CH), Kedrion S.p.A. (IT), Biotest AG (DE), LFB Group (FR), Hualan Biological Engineering Inc. (CN) are some of the major participants in the global market.

**Report ID:** MRFR/HC/5928-CR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397

---

## Market Summary

April 01, 2026- According to Market Research Future analysis, the Plasma Fractionation Market Size was estimated at 31.82 USD Billion in 2024. The Plasma Fractionation industry is projected to grow from 33.92 USD Billion in 2025 to 64.22 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.5% during the forecast period 2025 - 2035. North America led the market with over 45% share, generating around USD 14.3 billion in revenue.
 
Rising prevalence of chronic and rare disorders such as immunodeficiency and hemophilia is driving demand for plasma-derived therapies. Increasing use of immunoglobulins and clotting factors supports plasma fractionation expansion across hospitals and specialty care globally.
 
According to the Centers for Disease Control and Prevention (CDC), hemophilia affects approximately 1 in 5,000 male births globally, creating sustained demand for clotting factor concentrates derived from plasma fractionation. WHO highlights growing need for immunoglobulin therapies in immune deficiency management, reinforcing global treatment accessibility trends.

## Market Drivers

### Expansion of Healthcare Infrastructure

The ongoing expansion of healthcare infrastructure in various regions is significantly influencing the Plasma Fractionation Market. As countries invest in improving their healthcare systems, the availability of advanced medical facilities and technologies is increasing. This expansion facilitates better access to plasma-derived therapies, which are essential for treating a range of medical conditions. For instance, the establishment of specialized treatment centers and blood banks enhances the collection and processing of plasma, thereby supporting the growth of the market.
 
Moreover, the integration of state-of-the-art technologies in healthcare facilities is likely to improve the efficiency of plasma fractionation processes. As a result, the market may witness a surge in demand for plasma-derived products, driven by the enhanced capabilities of healthcare providers to deliver effective treatments.

### Rising Demand for Personalized Medicine

The growing trend towards personalized medicine is significantly impacting the Plasma Fractionation Market. As healthcare shifts towards tailored treatment approaches, the demand for plasma-derived therapies that can be customized to individual patient needs is likely to increase. Personalized medicine aims to optimize therapeutic outcomes by considering genetic, environmental, and lifestyle factors.
 
This approach aligns well with the capabilities of plasma fractionation, which allows for the development of specific products targeting unique patient profiles. Recent studies suggest that personalized therapies can lead to improved patient outcomes and reduced healthcare costs, further driving interest in plasma-derived products. Consequently, the market may experience a surge in demand as healthcare providers and patients seek more effective and individualized treatment options.

### Growing Awareness of Immunoglobulin Therapies

The increasing awareness regarding the benefits of immunoglobulin therapies is a notable driver for the Plasma Fractionation Market. Immunoglobulins, derived from human plasma, play a vital role in treating various immunodeficiency disorders and autoimmune diseases. As healthcare professionals and patients become more informed about these therapies, the demand for immunoglobulin products is likely to rise. Recent data indicates that the immunoglobulin market is projected to reach approximately USD 20 billion by 2026, reflecting a robust growth trajectory.
 
This trend suggests that the market will experience heightened interest and investment as stakeholders recognize the therapeutic potential of immunoglobulins. Additionally, the increasing number of clinical trials and research initiatives focused on immunoglobulin therapies may further stimulate market growth, as new applications and formulations are explored.

### Regulatory Support for Plasma-Derived Products

Regulatory support for plasma-derived products is emerging as a significant driver for the Plasma Fractionation Market. Governments and regulatory bodies are increasingly recognizing the importance of plasma therapies in treating various medical conditions. This recognition has led to the establishment of favorable policies and guidelines that facilitate the approval and commercialization of plasma-derived products. For instance, streamlined regulatory processes can expedite the introduction of new therapies into the market, thereby enhancing patient access to essential treatments.
 
Furthermore, the emphasis on safety and efficacy in the approval process is likely to bolster consumer confidence in plasma-derived products. As a result, the market may benefit from increased investment and innovation, as companies seek to develop new and improved therapies that meet regulatory standards.

### Increasing Incidence of Hematological Disorders

The rising prevalence of hematological disorders, such as hemophilia and multiple myeloma, is a crucial driver for the Plasma Fractionation Market. As these conditions require specific plasma-derived products for treatment, the demand for plasma fractionation is expected to grow. According to recent estimates, the incidence of hemophilia is approximately 1 in 5,000 male births, indicating a substantial patient population reliant on plasma-derived therapies.
 
This trend suggests that healthcare providers are increasingly focusing on developing effective treatment options, thereby propelling the market forward. Furthermore, advancements in diagnostic techniques are likely to enhance early detection, leading to timely interventions and increased demand for plasma products. Consequently, the market is poised for growth as healthcare systems adapt to the rising burden of hematological disorders.

## Future Outlook

The Plasma Fractionation Market size is projected to reach USD 64.22 Billion by 2035, growing at a CAGR of 6.59%, driven by increasing demand for immunoglobulins and advancements in fractionation technologies.

**New opportunities:**

- Expansion of [contract manufacturing services](https://www.marketresearchfuture.com/reports/contract-manufacturing-service-market-41421) for biopharmaceutical companies. Development of innovative plasma-derived therapies targeting rare diseases. Investment in automated plasma collection and processing technologies.

By 2035, the Plasma Fractionation Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Immunology (Largest) vs. Hematology (Fastest-Growing)

The application segment primarily comprises neurology, hematology, general medicine, and immunology. Currently, immunology holds the largest Plasma Fractionation Market share at 45% within this segment, driven by the increasing prevalence of immune disorders and the demand for immunoglobulin therapies. Hematology, while smaller in proportion compared to immunology, is rapidly gaining traction and is recognized as the fastest-growing segment due to advancements in therapeutic developments and rising blood disorder cases.

Immunology (Dominant) vs. Hematology (Emerging)

Immunology plays a dominant role in the Plasma Fractionation Market, characterized by its substantial contribution towards enabling the production of immunoglobulins, which are vital for treating a variety of immune system disorders. This segment benefits significantly from the continuous innovation in therapies that target autoimmune diseases and primary immunodeficiencies. On the other hand, hematology, as an emerging segment, is witnessing rapid growth driven by increasing incidences of hematological disorders such as hemophilia and anemia. The focus on developing new therapies and treatments, coupled with enhancements in blood component collection and fractionation technologies, positions hematology as a vital area of future development within the market.

### By Product Type: Immunoglobulin (Largest) vs. Albumin (Fastest-Growing)

The Immunoglobulin continues to dominate with the largest Plasma Fractionation Market share at 50% among product types, owing to its extensive application in immunotherapy and autoimmune disorders. Albumin, while currently holding a smaller share, is rapidly gaining traction, particularly in critical care and surgical settings, reflecting a significant shift in market dynamics. The growth of these product types is influenced by their therapeutic benefits and increasing clinical demand. The overall growth of the market is driven by advancements in biotechnology and rising prevalence of diseases requiring plasma-derived therapies. Furthermore, regulatory approvals for new treatments and increasing investment in research are propelling the development of emerging products like Albumin. As healthcare systems evolve, the importance of efficient and safe plasma products remains paramount to meet growing patient needs.

Immunoglobulin (Dominant) vs. Protease Inhibitors (Emerging)

Immunoglobulin represents the dominant force in the Plasma Fractionation Market, praised for its wide-ranging applications in treating immune deficiencies and various chronic diseases. Its established presence in clinical settings solidifies its position, driven by strong demand from healthcare professionals. On the other hand, Protease Inhibitors are emerging as a significant focus for research and development within the market. Although currently less prevalent, their potential to treat viral infections, including Hepatitis and HIV, positions them favorably for future growth. As healthcare trends shift toward innovative therapies, both products will play distinct roles; Immunoglobulin bolstering established treatments, while Protease Inhibitors expand therapeutic options.

### By End User: Hospitals (Largest) vs. Pharmaceutical Companies (Fastest-Growing)

Hospitals dominate the end-user segment with the largest Plasma Fractionation Market share at 55%, as they rely on plasma-derived products for patient treatments and surgical procedures. Conversely, pharmaceutical companies are rapidly emerging as a significant stakeholder in this market, driven by the increasing demand for innovative therapies, including immunoglobulins and clotting factors. Together, these two segments reflect the broader applications of plasma products in healthcare, underscoring the vital role of medical institutions and drug manufacturers in advancing treatment options.

Blood Banks (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Blood banks represent a dominant force in the Plasma Fractionation Market, serving as key collectors and processors of plasma. They leverage advanced technologies to ensure the safety and efficacy of plasma products, which are essential for transfusions and other medical applications. On the other hand, ambulatory surgical centers (ASCs) are emerging as a vital segment, gaining traction due to the shift towards outpatient care. These centers benefit from streamlined operations and the ability to provide immediate access to plasma therapies, driving their growth. As healthcare continues to evolve, both blood banks and ASCs play pivotal roles in the distribution and utilization of plasma-derived treatments.

### By Technology: Centrifugation (Largest) vs. Chromatography (Fastest-Growing)

Centrifugation holds the largest Plasma Fractionation Market share at 60% due to its established efficiency and reliability in separating plasma components. It is widely adopted across various healthcare settings. Conversely, Chromatography, while smaller in market share, is recognized for its rapid growth as it provides higher purity and specificity in plasma fractionation processes, attracting a growing number of applications.

Technology: Centrifugation (Dominant) vs. Chromatography (Emerging)

Centrifugation is a dominant technology in the Plasma Fractionation Market, known for its effectiveness in separating blood components through high-speed spinning. This technique is preferred for its scalability and cost-effectiveness, making it suitable for both large and small-scale operations. On the other hand, Chromatography is emerging as a pivotal technology, particularly valued for its ability to achieve high-resolution separation. It utilizes sophisticated methods to ensure the purity of plasma derivatives, which is increasingly demanded in therapeutic applications. As regulatory standards tighten and the demand for quality increases, chromatography is expected to see significant uptake, driving innovation in the sector.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America leads in the Plasma Fractionation Market size, accounting for over 45% of the global revenue in 2024. The region benefits from advanced healthcare infrastructure, high demand for immunoglobulins, and supportive regulatory frameworks. The increasing prevalence of chronic diseases and the aging population are significant growth drivers.

Regulatory bodies like the FDA ensure stringent quality standards, further boosting market confidence. The United States is the leading country in this region, with major players such as Grifols and CSL Behring establishing a strong presence. Canada also contributes significantly, focusing on research and development in [biopharmaceuticals](https://www.marketresearchfuture.com/reports/biopharmaceuticals-market-8439). The competitive landscape is characterized by innovation and strategic partnerships among key players, enhancing product offerings and market reach.

Strong demand for immunoglobulins and advanced healthcare infrastructure drives North America’s leadership in plasma fractionation. CDC reports hemophilia affects about 20,000 individuals in the U.S., sustaining demand for clotting therapies. High chronic disease prevalence and strong plasma donation systems further strengthen market expansion across the region.

### Europe : Emerging Market with Growth Potential

Europe Plasma Fractionation Market size was valued at USD 9.55 billion in 2024, making it the second-largest regional market with a 30% share. The region is witnessing increased demand for plasma-derived therapies, driven by rising healthcare expenditures and a growing patient population. Regulatory support from the European Medicines Agency (EMA) is pivotal in ensuring product safety and efficacy, which fosters market growth and innovation.

Germany, France, and the UK are the leading countries in this market, with significant contributions from companies like Octapharma and LFB Group. The competitive landscape is evolving, with a focus on expanding production capacities and enhancing product portfolios. Collaborations between public and private sectors are also on the rise, aiming to improve access to plasma therapies across Europe.

Europe’s growth is driven by increasing demand for plasma-derived therapies and strong regulatory frameworks ensuring product safety. ECDC supports advanced blood safety monitoring systems across EU nations, improving plasma collection efficiency. Rising patient population requiring immunoglobulin therapies strengthens regional adoption and healthcare accessibility across major economies.

### Asia-Pacific : Rapidly Growing Market Segment

Asia-Pacific is an emerging powerhouse in the market, holding approximately 20% of the global share. The region is experiencing rapid growth due to increasing healthcare investments, rising awareness of plasma-derived therapies, and a growing population. Countries like China and India are witnessing significant demand, driven by the rising incidence of hemophilia and other blood-related disorders, alongside supportive government initiatives.

China is the largest market in the region, with key players like Hualan Biological Engineering leading the charge. India is also making strides, with a focus on expanding its plasma collection and processing capabilities. The competitive landscape is characterized by both local and international players, fostering innovation and improving access to essential therapies across the region.

### Middle East and Africa : Untapped Market with Potential

The Middle East and Africa represent an untapped market for plasma fractionation, holding about 5% of the global share. The region is gradually recognizing the importance of plasma-derived therapies, driven by increasing healthcare investments and a rising prevalence of chronic diseases. Regulatory frameworks are evolving, with governments focusing on improving healthcare infrastructure and access to essential treatments, which is expected to catalyze market growth in the coming years.

Countries like South Africa and the UAE are leading the way in adopting plasma therapies, with a growing number of healthcare facilities investing in plasma collection and processing. The competitive landscape is still developing, with opportunities for both local and international players to establish a foothold in this emerging market. Strategic partnerships and collaborations are likely to play a crucial role in expanding market presence and improving patient access to therapies.

## Competitive Benchmarking

The Plasma Fractionation Market has witnessed significant growth over recent years, driven by the increasing demand for plasma-derived therapies and the rising prevalence of various disorders such as hemophilia, immune deficiencies, and certain cancers.
 
This market is characterized by the presence of numerous key players, each striving to enhance their product offerings and expand their market share.Competitive insights into this market reveal a landscape where innovation, strategic partnerships, and regulatory considerations play vital roles. Plasma manufacturers are focusing on research and development to improve existing advanced plasma products, while also exploring new therapeutic areas to address unmet medical needs.
 

Additionally, the blood plasma market is experiencing consolidation through mergers and acquisitions as organizations aim to leverage synergies and streamline their operations.LFB Group has established itself as a prominent player in the market through its emphasis on high-quality products and patient-centric solutions. The company benefits from its strong research and development capabilities, allowing it to introduce innovative plasma-derived therapies that meet the increasing global healthcare demands.
 
LFB Group's market presence is bolstered by its commitment to safety and efficacy, which resonates well with healthcare providers and patients alike. The organization has developed a wide range of immunoglobulin and clotting factor products that cater to various therapeutic needs, making it a trusted name within plasma industries. Its collaborations with academic institutions and healthcare organizations further enhance its competitive position, emphasizing its role as a leader in providing specialized plasma-derived therapies globally.Takeda Pharmaceutical is another key participant in the market, recognized for its extensive portfolio of biologics and Takeda plasma derived therapies. The company offers a range of products, including immunoglobulins, clotting factors, and other therapeutic proteins, which serve various medical conditions.
 
Takeda's strength lies in its robust global presence, allowing it to reach a wide patient population and address local healthcare challenges effectively. With a strong focus on research and strategic partnerships, Takeda is actively engaged in mergers and acquisitions to enhance its technological capabilities and expand its product offerings.
These initiatives not only bolster its market position but also promote innovation in plasma fractionation technologies. The company’s commitment to patient access and improving health outcomes further solidifies its standing as a leader in the global blood plasma market, enhancing its competitiveness in this dynamic industry.

## Recent News & Developments

Significant news developments in the Plasma Fractionation Market include accelerated growth driven by increasing demand for immunoglobulin therapies and advancements in plasma-derived products. Companies like Grifols and CSL Behring are enhancing their production capabilities through investments in new facilities and technology.

In October 2023, Takeda Pharmaceutical announced plans to expand its manufacturing footprint in response to heightened demand, illustrating the competitive landscape.

Recent mergers and acquisitions have also shaped plasma industries; for instance, in September 2023, ADMA Biologics finalized its acquisition of a specialized plasma collection center to strengthen its supply chain.

Additionally, in December 2022, Octapharma and Hualan Biological Engineering formed a collaborative agreement to enhance production efficiency, indicating strategic alliances within the sector.

Moreover, technological advancements in plasma fractionation processes are improving yield and reducing costs, benefiting plasma manufacturers like Emergent BioSolutions and Biotest AG.

The overall market valuation continues to grow as consumer awareness of plasma-derived therapies rises, with emerging markets contributing to increasing investments. This growth trend emphasizes the importance of operational excellence and innovation in the industry's future endeavors while navigating regulatory landscapes in various global regions.

## Report Scope

| MARKET SIZE 2024 | 31.82(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 33.92(USD Billion) |
| MARKET SIZE 2035 | 64.22(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.59% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company Limited (JP), Octapharma (CH), Kedrion S.p.A. (IT), Biotest AG (DE), LFB Group (FR), Hualan Biological Engineering Inc. (CN) |
| Segments Covered | Applications, Product Type, End Users, Technology, Regional |
| Key Market Opportunities | Advancements in immunoglobulin therapies drive growth in the market. |
| Key Market Dynamics | Rising demand for immunoglobulins drives innovation and competition in the market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Plasma Fractionation Market?**
A: As of 2024, the Plasma Fractionation Market was valued at 31.82 USD Billion.

**Q: What is the projected market size for the market by 2035?**
A: The market is projected to reach 64.22 USD Billion by 2035.

**Q: What is the expected CAGR for the market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during 2025 - 2035 is 6.59%.

**Q: Which application segment is anticipated to have the highest valuation in 2035?**
A: The General Medicine application segment is projected to reach between 10.0 and 20.0 USD Billion by 2035.

**Q: What are the key product types in the market?**
A: Key product types include Immunoglobulin, Albumin, Coagulation Factors, and Protease Inhibitors.

**Q: Which end user segment is expected to dominate the market by 2035?**
A: The Hospitals end user segment is anticipated to grow to between 12.0 and 25.0 USD Billion by 2035.

**Q: What technologies are utilized in the Plasma Fractionation process?**
A: Technologies used include Centrifugation, Chromatography, Precipitation, and Filtration.

**Q: Who are the leading companies in the Plasma Fractionation Market?**
A: Key players include Grifols, CSL Behring, Takeda Pharmaceutical Company Limited, and Octapharma.

**Q: What is the projected valuation for the Immunoglobulin product type by 2035?**
A: The Immunoglobulin product type is expected to reach between 12.0 and 25.0 USD Billion by 2035.

**Q: How does the Plasma Fractionation Market's growth compare across different segments?**
A: The market shows varied growth across segments, with Hematology and Immunology also projected to see substantial increases.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397*